Nowadays, various biomarkers for MS are actively studied in relation to diagnostics, prognostics, monitoring, and the evaluation of therapy effectiveness such us NfL, glial fibrillary acidic protein, and other proteins. The gene discussed is NEFL; the disease is myeloid sarcoma.